Immutep (IMM.AX) Stock Price

Immutep Price

ASX·CLOSED
0.05AUD-0.0030 (-5.31 %)
Market closed

Revenue at Immutep has contracted by 19.7% per year over the past 19 years to 60,100.00 AUD. For Immutep, the net margin of -102,220.0% is down versus -9,559.7% a few years ago. The consensus 12-month price target for Immutep is 1.13 AUD, about 1,958.5% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 53% above its 52-week low.

Immutep stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Immutep over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Immutep stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Immutep's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Immutep Stock Price History
DateImmutep Price
7/14/20260.05 AUD
7/13/20260.06 AUD
7/10/20260.05 AUD
7/9/20260.05 AUD
7/8/20260.05 AUD
7/7/20260.05 AUD
7/6/20260.05 AUD
7/3/20260.05 AUD
7/2/20260.06 AUD
7/1/20260.06 AUD
6/30/20260.05 AUD
6/29/20260.05 AUD
6/26/20260.05 AUD
6/25/20260.05 AUD
6/24/20260.05 AUD
6/23/20260.05 AUD
6/22/20260.05 AUD
6/19/20260.05 AUD
6/18/20260.05 AUD
6/17/20260.05 AUD
6/16/20260.05 AUD
6/15/20260.05 AUD
6/12/20260.05 AUD
6/11/20260.05 AUD
6/10/20260.05 AUD
6/9/20260.05 AUD
6/5/20260.05 AUD
6/4/20260.05 AUD
6/3/20260.05 AUD
6/2/20260.05 AUD
6/1/20260.05 AUD
5/29/20260.05 AUD
5/28/20260.05 AUD
5/27/20260.05 AUD
5/26/20260.06 AUD
5/25/20260.06 AUD
5/22/20260.06 AUD
5/21/20260.06 AUD
5/20/20260.06 AUD
5/19/20260.06 AUD
5/18/20260.06 AUD
5/15/20260.06 AUD
5/14/20260.06 AUD
5/13/20260.06 AUD
5/12/20260.06 AUD
5/11/20260.06 AUD
5/8/20260.06 AUD
5/7/20260.06 AUD
5/6/20260.06 AUD
5/5/20260.06 AUD
5/4/20260.06 AUD
5/1/20260.06 AUD
4/30/20260.06 AUD
4/29/20260.06 AUD
4/28/20260.06 AUD
4/27/20260.07 AUD
4/24/20260.07 AUD
4/23/20260.07 AUD
4/22/20260.07 AUD
4/21/20260.07 AUD
4/20/20260.07 AUD
4/17/20260.07 AUD
4/16/20260.08 AUD
4/15/20260.07 AUD
4/14/20260.04 AUD
4/13/20260.04 AUD
4/10/20260.04 AUD
4/9/20260.04 AUD
4/8/20260.05 AUD
4/7/20260.04 AUD
4/2/20260.04 AUD
4/1/20260.05 AUD
3/31/20260.05 AUD
3/30/20260.05 AUD
3/27/20260.05 AUD
3/26/20260.05 AUD
3/25/20260.05 AUD
3/24/20260.05 AUD
3/23/20260.05 AUD
3/20/20260.05 AUD
3/19/20260.05 AUD
3/18/20260.05 AUD
3/17/20260.05 AUD
3/16/20260.06 AUD
3/13/20260.05 AUD
3/12/20260.40 AUD
3/11/20260.40 AUD
3/10/20260.40 AUD
3/9/20260.40 AUD
3/6/20260.40 AUD
3/5/20260.38 AUD
3/4/20260.35 AUD
3/3/20260.37 AUD
3/2/20260.38 AUD
2/27/20260.38 AUD
2/26/20260.40 AUD
2/25/20260.39 AUD
2/24/20260.38 AUD
2/23/20260.39 AUD
2/20/20260.40 AUD
2/19/20260.40 AUD
2/18/20260.38 AUD
2/17/20260.38 AUD
2/16/20260.37 AUD
2/13/20260.37 AUD
2/12/20260.38 AUD
2/11/20260.39 AUD
2/10/20260.38 AUD
2/9/20260.37 AUD
2/6/20260.37 AUD
2/5/20260.38 AUD
2/4/20260.38 AUD
2/3/20260.40 AUD
2/2/20260.41 AUD
1/30/20260.40 AUD
1/29/20260.43 AUD
1/28/20260.44 AUD
1/27/20260.44 AUD
1/23/20260.46 AUD
1/22/20260.41 AUD
1/21/20260.41 AUD
1/20/20260.42 AUD
1/19/20260.43 AUD
1/16/20260.44 AUD
1/15/20260.46 AUD
1/14/20260.46 AUD
1/13/20260.45 AUD
1/12/20260.44 AUD
1/9/20260.44 AUD
1/8/20260.44 AUD
1/7/20260.43 AUD
1/6/20260.43 AUD
1/5/20260.43 AUD
1/2/20260.43 AUD
12/31/20250.41 AUD
12/30/20250.43 AUD
12/29/20250.44 AUD
12/24/20250.41 AUD
12/23/20250.41 AUD
12/22/20250.40 AUD
12/19/20250.40 AUD
12/18/20250.40 AUD
12/17/20250.39 AUD
12/16/20250.37 AUD
12/15/20250.37 AUD
12/12/20250.38 AUD
12/11/20250.37 AUD
12/10/20250.34 AUD
12/9/20250.32 AUD
12/8/20250.25 AUD
12/5/20250.26 AUD
12/4/20250.25 AUD
12/3/20250.25 AUD
12/2/20250.28 AUD
12/1/20250.29 AUD
11/28/20250.31 AUD
11/27/20250.28 AUD
11/26/20250.27 AUD
11/25/20250.26 AUD
11/24/20250.26 AUD
11/21/20250.26 AUD
11/20/20250.26 AUD
11/19/20250.26 AUD
11/18/20250.28 AUD
11/17/20250.28 AUD
11/14/20250.28 AUD
11/13/20250.26 AUD
11/12/20250.27 AUD
11/11/20250.26 AUD
11/10/20250.25 AUD
11/7/20250.25 AUD
11/6/20250.25 AUD
11/5/20250.26 AUD
11/4/20250.27 AUD
11/3/20250.28 AUD
10/31/20250.28 AUD
10/30/20250.28 AUD
10/29/20250.30 AUD
10/28/20250.28 AUD
10/27/20250.29 AUD
10/24/20250.31 AUD
10/23/20250.29 AUD
10/22/20250.31 AUD
10/21/20250.31 AUD
10/20/20250.29 AUD
10/17/20250.31 AUD
10/16/20250.31 AUD
10/15/20250.30 AUD
10/14/20250.29 AUD
10/13/20250.29 AUD
10/10/20250.31 AUD
10/9/20250.29 AUD
10/8/20250.29 AUD
10/7/20250.28 AUD
10/6/20250.29 AUD
10/3/20250.28 AUD
10/2/20250.28 AUD
10/1/20250.26 AUD
9/30/20250.26 AUD
9/29/20250.26 AUD
9/26/20250.25 AUD
9/25/20250.25 AUD
9/24/20250.25 AUD
9/23/20250.25 AUD
9/22/20250.25 AUD
9/19/20250.25 AUD
9/18/20250.25 AUD
9/17/20250.25 AUD
9/16/20250.25 AUD
9/15/20250.26 AUD
9/12/20250.23 AUD
9/11/20250.24 AUD
9/10/20250.23 AUD
9/9/20250.23 AUD
9/8/20250.25 AUD
9/5/20250.23 AUD
9/4/20250.25 AUD
9/3/20250.24 AUD
9/2/20250.25 AUD
9/1/20250.23 AUD
8/29/20250.23 AUD
8/28/20250.25 AUD
8/27/20250.25 AUD
8/26/20250.25 AUD
8/25/20250.25 AUD
8/22/20250.25 AUD
8/21/20250.25 AUD
8/20/20250.25 AUD
8/19/20250.26 AUD
8/18/20250.26 AUD
8/15/20250.26 AUD
8/14/20250.25 AUD
8/13/20250.25 AUD
8/12/20250.26 AUD
8/11/20250.26 AUD
8/8/20250.27 AUD
8/7/20250.28 AUD
8/6/20250.26 AUD
8/5/20250.26 AUD
8/4/20250.26 AUD
8/1/20250.26 AUD
7/31/20250.27 AUD
7/30/20250.26 AUD
7/29/20250.27 AUD
7/28/20250.26 AUD
7/25/20250.26 AUD
7/24/20250.26 AUD
7/23/20250.24 AUD
7/22/20250.25 AUD
7/21/20250.25 AUD
7/18/20250.26 AUD
7/17/20250.26 AUD
7/16/20250.25 AUD
Access this data via the Eulerpool API
Get Free API Key

Immutep Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
191,700.00 AUD
-48.20 M AUD
-39.90 M AUD
Jan 1, 2024
119,600.00 AUD
-50.41 M AUD
-42.72 M AUD
Jan 1, 2025
60,100.00 AUD
-70.14 M AUD
-61.43 M AUD
Jan 1, 2026 (e)
24.35 M AUD
-61.00 M AUD
-79.65 M AUD
Jan 1, 2027 (e)
5.87 M AUD
-64.49 M AUD
-88.96 M AUD
Jan 1, 2028 (e)
108.98 M AUD
-72.31 M AUD
-51.46 M AUD
Jan 1, 2029 (e)
252.64 M AUD
107.12 M AUD
-13.23 M AUD
Jan 1, 2030 (e)
653.40 M AUD
139.86 M AUD
140.13 M AUD

Immutep Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 16, 2026, 12:47 AM
 
REVENUEB AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESB
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
––0.010.010.01–––––0.020.010.110.250.651.12
100.00100.0075.00-14.29116.67––––––-79.172,060.00133.33159.1371.52
-1,600.00-800.00-457.14-533.33-246.15–––––-133.33-640.00-29.63-12.70-4.90-2.86
-32.00-32.00-32.00-32.00-32.00-13.00-26.00-32.00-32.00-32.00-32.00-32.00-32.00-32.00-32.00-32.00
-62.00-9.00-12.00-18.00-13.00-29.00-32.00-39.00-42.00-61.00-79.00-88.00-51.00-13.00140.00361.00
93.75-85.4833.3350.00-27.78123.0810.3421.887.6945.2429.5111.39-42.05-74.51-1,176.92157.86
0.230.210.260.320.410.610.870.901.211.461.461.461.461.461.461.46
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Immutep generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Immutep retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Immutep's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Immutep has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Immutep's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Immutep stock margins

The Immutep margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immutep. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immutep.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-4,274.30 %
-7,793.48 %
-9,559.65 %
Jan 1, 2022
-10,467.77 %
-15,181.60 %
-12,661.48 %
Jan 1, 2023
-17,083.99 %
-25,142.62 %
-20,811.89 %
Jan 1, 2024
-17,083.99 %
-42,144.65 %
-35,716.22 %
Jan 1, 2025
-17,083.99 %
-116,703.99 %
-102,219.97 %
Jan 1, 2026 (e)
-17,083.99 %
-250.54 %
-327.12 %
Jan 1, 2027 (e)
-17,083.99 %
-1,099.27 %
-1,516.24 %
Jan 1, 2028 (e)
-17,083.99 %
-66.35 %
-47.22 %

Immutep Stock Revenue, EBIT, Earnings per Share

The Immutep earnings per share therefore indicates how much revenue Immutep has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 AUD
-0.04 AUD
-0.05 AUD
Jan 1, 2022
0.00 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2023
0.00 AUD
-0.05 AUD
-0.04 AUD
Jan 1, 2024
0.00 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2025
0.00 AUD
-0.05 AUD
-0.04 AUD
Jan 1, 2026 (e)
0.02 AUD
-0.04 AUD
-0.05 AUD
Jan 1, 2027 (e)
0.00 AUD
-0.04 AUD
-0.06 AUD
Jan 1, 2028 (e)
0.07 AUD
-0.05 AUD
-0.04 AUD

Immutep business model & stock analysis

Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2001 and is headquartered in Sydney, Australia. The history of Immutep began with the discovery of a new type of T-cell receptor, known as lymphocyte activation gene-3 (LAG-3) receptors, which are involved in the activation of T-cells. The company used this knowledge to develop a platform of immunotherapeutics based on the stimulation of LAG-3 receptors, with the goal of enhancing the body's immune response against cancer and autoimmune diseases. Immutep's business model is based on the development and commercialization of immunotherapeutics that target LAG-3 receptors. The company focuses on the clinical development of therapeutics targeting various stages of cancer, such as lung cancer, prostate cancer, and breast cancer. Additionally, the company is also developing therapeutics for the treatment of autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and Crohn's disease. Immutep is divided into various divisions to coordinate its activities in the areas of research and clinical development. These divisions include clinical development, research and development, and the production of immunotherapeutics. In the clinical development division, Immutep focuses on demonstrating the safety and efficacy of its immunotherapeutics in the treatment of cancer and autoimmune diseases. The company conducts clinical trials to evaluate the effectiveness of its therapeutics and obtain regulatory approval. Immutep's research and development department focuses on developing innovative immunotherapeutics based on LAG-3 receptors. The company has developed several patented technologies that enhance the effectiveness of the therapeutics and increase the body's tolerance to them. Immutep also operates a production division specializing in the manufacturing of immunotherapeutics. The company has production facilities in Europe and Asia, allowing it to distribute its therapeutics worldwide. The company offers a range of immunotherapeutics based on the stimulation of LAG-3 receptors. These therapeutics have been specifically developed for the treatment of cancer and autoimmune diseases and have the potential to enhance the body's immune response against these conditions. Immutep's products include IMP321, an immunotherapeutic specifically developed for the treatment of prostate cancer, and IMP701, an immunotherapeutic specifically developed for the treatment of lung cancer. Additionally, the company has several new therapeutics in clinical development, including IMP761 for the treatment of systemic lupus erythematosus and IMP731 for the treatment of Crohn's disease. Immutep is a leading company in the development of immunotherapeutics based on LAG-3 receptors. The company has a strong pipeline of therapeutics in clinical development and is well-positioned to benefit from the growing demand for immunotherapeutics for the treatment of cancer and autoimmune diseases. With its patented technologies and expertise in clinical development of immunotherapeutics, Immutep is well-equipped to grow and solidify its position as a leading company in this field.

Immutep SWOT Analysis

Strengths

Immutep Ltd has a strong portfolio of potential immunotherapy drugs, which have shown promising results in early stage trials. These drugs have the potential to revolutionize cancer treatment by enhancing the body's immune response to fight the disease.

The company has a highly skilled and experienced research and development team, bolstered by collaborations with renowned research institutions and academic partners. This allows Immutep to stay at the forefront of immunotherapy research and develop innovative solutions.

Immutep also possesses valuable intellectual property rights and patents, providing a competitive advantage in the rapidly growing immunotherapy market.

Weaknesses

Immutep Ltd currently relies heavily on investment and partnership funding to support its research and development efforts. A lack of diversification in funding sources could pose a risk if there are any disruptions or limitations in securing such funds.

Due to the highly specialized nature of immunotherapy, there is a risk of potential regulatory hurdles and lengthy approval processes before Immutep's drugs can be commercialized and generate revenue.

As a relatively small and emerging biopharmaceutical company, Immutep may face challenges in scaling up manufacturing capabilities and establishing a global presence to effectively compete with larger industry players.

Opportunities

The growing demand for effective cancer treatment options, especially those that harness the power of the immune system, presents a significant market opportunity for Immutep Ltd. The increasing prevalence of cancer worldwide further strengthens this potential market.

Immutep's partnerships with established pharmaceutical companies can provide access to additional resources, expertise, and distribution capabilities, facilitating the development and commercialization of its immunotherapy drugs.

Expansion into new geographic markets and diversifying the application of immunotherapy drugs beyond cancer, such as autoimmune diseases, could open up further revenue streams for the company.

Threats

The competitive landscape in the immunotherapy market is intense, with numerous companies investing heavily in research and development. Immutep Ltd faces the risk of being outpaced by competitors with more advanced therapies or greater financial resources.

Market volatility and regulatory changes can impact investment sentiment and funding availability, which may affect Immutep's ability to continue its research and development activities at the desired pace.

There is also the potential risk of unforeseen side effects or limited efficacy in clinical trials, which could hinder the approval and commercial success of Immutep's immunotherapy drugs.

Immutep Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Immutep historical P/E ratio, EBIT multiple, and P/S ratio

Immutep annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Immutep shares outstanding

The number of shares of Immutep was 1.46 B in 2025. This indicates how many shares Immutep is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
609.91 M Stocks
Jan 1, 2022
870.34 M Stocks
Jan 1, 2023
900.69 M Stocks
Jan 1, 2024
1.21 B Stocks
Jan 1, 2025
1.46 B Stocks
Jan 1, 2026 (e)
1.46 B Stocks
Jan 1, 2027 (e)
1.46 B Stocks
Jan 1, 2028 (e)
1.46 B Stocks

Immutep stock splits

In Immutep's history, there have been no stock splits.

Current Immutep forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
12.60 %
Buy88.89 % (8)
Hold11.11 % (1)
Sell0.00 % (0)
12M Price Target
1.13
Last Price
0.05
Currency
AUD
12M Return Potential
1,958.55 %
LTM Return
0 %

Immutep Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
2/22/2024-0.02AUD1.06 MAUD2024 Q2
8/29/20230.12AUD0.00AUD2023 Q4
2/21/2023-0.02AUD0.00AUD2023 Q2
7/28/2022-0.02AUD1.35 MAUD2022 Q4
2/23/2022-0.02AUD3.04 MAUD2022 Q2
8/21/2018-0.02AUD1.70 MAUD2018 Q4

EESG©

Eulerpool ESG Scorecard© for the Immutep stock

56/100
53
Environment
99
Social
16
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees68
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Immutep shareholder structure

% Name
15.86031%
The Bank of New York Mellon Corporation
The Bank of New York Mellon Corporation
13.95752%
Regal Funds Management Pty. Ltd.
Regal Funds Management Pty. Ltd.
5.01974%
MLC Investments Limited
MLC Investments Limited
4.35978%
Fidelity International
Fidelity International
3.80203%
IOOF Investment Management Ltd.
IOOF Investment Management Ltd.
2.61492%
FIL Gestion
FIL Gestion

Immutep Executives and Management Board

MV

Mr. Marc Voigt

Chief Executive Officer, Executive Director · since 2012

Compensation1.06 M AUD
FV

Mr. Florian Vogl

Chief Medical Officer

Compensation955,823.00 AUD
FT

Dr. Frederic Triebel

Chief Scientific Officer, Executive Director · since 2014

Compensation864,436.00 AUD
DM

Ms. Deanne Miller

Chief Operating Officer, General Counsel, Joint Company Secretary

Compensation565,233.00 AUD
RH

Dr. Russell Howard

Independent Non-Executive Chairman of the Board

Compensation163,519.00 AUD

Immutep Supply Chain

Immutep Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
11 companies
#Name1M3M6M1Y2YTrend
1
Laboratory Corp
0.27
0.34
0.77
0.51
0.81
2
Citigroup
Supplier
-0.20
0.16
0.36
0.75
0.81
3
Bank of New York Mellon
Supplier
0.40
0.52
0.66
0.37
0.76
4
Australian Ethical Investment
Supplier
-0.22
0.30
0.87
0.64
0.72
5
Enzo Biochem
Supplier
-0.34
0.27
0.48
0.52
0.71
#Name1M3M6M1Y2YTrend
1
GlaxoSmithKline
Supplier
-0.08
-0.36
-0.37
-0.70
-0.17
2
Merck & Co
Supplier
0.88
-0.15
-0.48
-0.30
-0.03
3
Novartis
Supplier
-0.70
-0.56
-0.68
-0.23
0.01

Frequently asked questions about Immutep

The business model of Immutep Ltd revolves around developing and commercializing immunotherapy treatments. Immutep Ltd focuses on the development of LAG-3 related products, which play a crucial role in regulating the immune system. By leveraging its expertise and technology, the company aims to treat a wide range of diseases, including cancer and autoimmune disorders. Immutep Ltd collaborates with various partners and conducts clinical trials to evaluate the safety and effectiveness of its therapies. Through strategic partnerships and licensing agreements, the company aims to bring its innovative treatments to market, ultimately improving patient outcomes and advancing the field of immunotherapy.

All fundamentals and in-depth analysis of Immutep

Our stock analysis for Immutep stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immutep. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Immutep Stock
Immutep Revenue→
Immutep Stock
Immutep Net Income→
Immutep Stock
Immutep P/E→
Immutep Stock
Immutep P/S→
Immutep Stock
Immutep EBIT→
Immutep Stock
Immutep Dividend→
Immutep Stock
Immutep Directors Dealings→
Immutep Stock
Immutep Stocks→
Immutep Stock
Immutep Market capitalization→
Immutep Stock
Immutep Debt→
Immutep Stock
Immutep Liabilities→
Immutep Stock
Immutep Equity→
Immutep Stock
Immutep AAQS→
Immutep Stock
Immutep Employees→
Immutep Stock
Immutep ROE→
Immutep Stock
Immutep ROA→
Immutep Stock
Immutep ROCE→
Immutep Stock
Immutep News→
Immutep Stock
Immutep Analyst Price Targets→

Health Stocks

Immutep Ltd ADRImmuron Ltd ADRImpediMedImmuronImplanetImmunovia AB (publ)Improve Medical Instruments CoImmunovantImugeneImmunotech LaboratoriesImunonImmunotech BiopharmAll Stocks A–Z →